The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Pulmonary/Critical Care. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Mon, 10 Aug 2026 09:22:41 GMT 2026 NEJM Group en-us 1440 Among patients who were unresponsive after cardiac arrest, conservative oxygen therapy did not increase 180-day survival with favorable function as compared with liberal oxygen therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2513814?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513814 The LOGICAL Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group 2026-08-06 Conservative Oxygen for Unresponsive Patients after Cardiac Arrest This review summarizes the classification, evaluation, risk stratification, and management of syncope. History, examination, electrocardiography, and orthostatic blood-pressure measurement identify the cause in most patients. https://www.nejm.org/doi/full/10.1056/NEJMcp2517255?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2517255 Rose Anne Kenny 2026-08-06 Syncope In unresponsive patients after cardiac arrest, a complex pathophysiological response including potential brain injury, myocardial dysfunction, and systemic ischemia–reperfusion injury is at play, in addition to the challenges of the underlying cause of cardiac arrest.1 This complex and unique, but heterogeneous, constellation has prompted clinicians and researchers to... https://www.nejm.org/doi/full/10.1056/NEJMe2609084?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2609084 Lars W. Andersen, Asger Granfeldt 2026-08-06 Oxygen Targets after Cardiac Arrest — A LOGICAL Finding This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies. https://www.nejm.org/doi/full/10.1056/NEJMra2502459?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2502459 Theodore E. Warkentin, Andreas Greinacher 2026-07-30 Platelet-Activating Anti–Platelet Factor 4 Disorders In the ICU, a resident is surrounded by deaths, each one leaving him with a sense of emptiness. Then a Christmas tragedy highlights medicine’s privilege of bearing witness to love as well as death. https://www.nejm.org/doi/full/10.1056/NEJMp2516818?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2516818 Tristan Jones 2026-07-23 Love and Death In a phase 3 trial involving patients with idiopathic pulmonary fibrosis, inhaled treprostinil was associated with a smaller decline in forced vital capacity and a lower risk of clinical worsening than placebo over 52 weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2512911?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2512911 Steven D. Nathan, Peter Smith, Chunqin Deng, Maria De Salvo, Wim Wuyts, Juana Pavie-Gallegos, Jin Woo Song, Mordechai R. Kramer, Christopher S. King, John A. Mackintosh, Daniel Chambers, Georgina Viviana Miranda, Natalie Breytenbach, Leigh Peterson, Heidi Bell, Kevin R. Flaherty, Juergen Behr, Vincent Cottin, the TETON-2 Trial Investigators* 2026-07-09 Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. https://www.nejm.org/doi/full/10.1056/NEJMoa2518990?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2518990 Dongsheng Yue, Meijuan Huang, Pingping Song, Yuejun Chen, Bin Li, Junke Fu, Jianji Guo, Chao Cheng, Qixun Chen, Shidong Xu, Hongxu Liu, Fang Lv, Jian Hu, Ke Jiang, Weimin Mao, Bo Shen, Feng Ye, Jie Li, Xueying Zhang, Shiping Guo, Bentong Yu, Yuming Zhu, Ming Wu, Wei Zheng, Fang Chen, Zhengfu He, Yuansong Bai, Hua Xin, Keneng Chen, Naiquan Mao, Yu Zhang, Bo Wang, Lei Zhang, Xingwu Chen, Xinyu Mei, Liyun Miao, Runjie Wang, Gaofeng Li, Juntao Yao, Jun Zhao, Chun Chen, Junfeng Liu, Li Wei, Xiaolong Yan, Bo Jin, Xianling Liu, Zhidong Liu, Hui Tian, Wenqun Xing, Lin Yang, Di Ge, Xiangnan Li, Shanqing Li, Yongxiang Song, Aimin Zang, Dahai Zhang, Wu Zhuang, Zijin Liu, Xiaobin Yuan, Tao Fu, Zhilin Shen, Xiaojun Zhang, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding, You Lu, Changli Wang, the ELEVATE Study Group* 2026-07-09 Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Among patients with idiopathic pulmonary fibrosis, inhaled treprostinil led to a smaller decline in forced vital capacity than placebo over 52 weeks. Cough and drug discontinuation were more common with treprostinil. https://www.nejm.org/doi/full/10.1056/NEJMoa2501488?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2501488 Steven D. Nathan, Peter Smith, Chunqin Deng, Christopher S. King, Maria De Salvo, S. Samuel Weigt, Sahil Pandya, Debabrata Bandyopadhyay, Joseph A. Lasky, Rachana Krishna, Nathan Hambly, Murali Ramaswamy, Jad Kebbe, Neil Ettinger, Jamie Gao, Youlan Rao, Natalie Breytenbach, Leigh Peterson, Heidi Bell, Juergen Behr, Vincent Cottin, Kevin R. Flaherty, the TETON-1 Trial Investigators* 2026-07-09 Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis During the acute phase of critical illness, early restrictive-dose enteral nutrition is preferred over parenteral nutrition to support gut integrity. Full-dose enteral nutrition increases the risk of adverse effects. https://www.nejm.org/doi/full/10.1056/NEJMra2506111?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2506111 Jayshil J. Patel, Stephen A. McClave 2026-07-09 Nutrition Therapy in Critically Ill Adults A 68-year-old man was evaluated in an outpatient clinic because of fatigue and dyspnea. Lung transplantation had been performed 15 months earlier. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2517856?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2517856 Hilary J. Goldberg, Harikrishnan Nandakumar, Brian C. Keller, Lida P. Hariri, Arthur Y. Kim, Briana N. Castillo 2026-07-09 Case 19-2026: A 68-Year-Old Man with Fatigue, Fever, and Hypoxemia Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease, with an estimated global yearly incidence of approximately 6 per 100,000 and a prevalence of approximately 18 per 100,000.1,2 Patients with IPF have progressive dyspnea that is commonly accompanied by a disabling cough, impaired quality of life,... https://www.nejm.org/doi/full/10.1056/NEJMe2606821?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2606821 Darren Taichman 2026-07-09 Preserving Lung Function in Idiopathic Pulmonary Fibrosis In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. https://www.nejm.org/doi/full/10.1056/NEJMoa2515820?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515820 Brett L. Houston, Daniel I. McIsaac, Rodney H. Breau, Salmaan Kanji, Peter Greenstreet, Meghan Andrews, Sinziana Avramescu, Hema S. Bagry, Robert Balshaw, Jayesh Daya, Kaitlin Duncan, Christopher C. Harle, Eric Jacobsohn, Tina Kerelska, Marshall Pitz, Paul Komenda, Sarah McIsaac, Tim Ramsay, Tarit Saha, Alan Tinmouth, Angela Recio, Daniel Szoke, Marshall Tenenbein, Sarah Slagerman, Dayna Solvason, Robert Talarico, Dean A. Fergusson, Ryan Zarychanski 2026-06-25 Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... https://www.nejm.org/doi/full/10.1056/NEJMe2603105?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603105 Michael F. Murphy, Ian Roberts 2026-06-25 TRACTION for Greater Surgical Use of Tranexamic Acid Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications. https://www.nejm.org/doi/full/10.1056/NEJMp2601256?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601256 Robert D. Brook, Sanjay Rajagopalan 2026-06-25 Improving Global Air-Quality Indices — The WHO’s New Roadmap The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. https://www.nejm.org/doi/full/10.1056/NEJMp2601300?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601300 Arianne Teherani, Rupa Basu, Sheri Weiser 2026-06-25 When Health Costs No Longer Count — Air Pollution and EPA Rulemaking Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. https://www.nejm.org/doi/full/10.1056/NEJMoa2516043?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516043 Jason E. Smith, Rebecca Cardigan, Emily Sanderson, Laura Silsby, Claire Rourke, Ed B.G. Barnard, Peter Basham, Grazia Antonacci, Richard Charlewood, Nikki Dallas, Jane Davies, Elizabeth Goodwin, Annie Hawton, Cara Hudson, Joanne Lucas, Katie Keen, Richard M. Lyon, Brodie Nolan, Gavin D. Perkins, Viona Rundell, Laura Smith, Simon J. Stanworth, Anne Weaver, Tom Woolley, Laura Green, the SWiFT Trial Group* 2026-06-18 Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2519001?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2519001 Suresh Vedantham, Susan R. Kahn, William A. Marston, Ido Weinberg, Akhilesh K. Sista, Elizabeth A. Magnuson, David J. Cohen, Suman M. Wasan, Mahmood K. Razavi, Samuel Z. Goldhaber, Kristen M. Sanfilippo, Anthony J. Comerota, Ezana M. Azene, Cassius Iyad Ochoa Chaar, Daniel A. Leung, K. Pallav Kolli, Sanjeeva P. Kalva, Nassir Rostambeigi, Ajinkya Desai, Kush R. Desai, Alfonso J. Tafur, Bhavraj Khalsa, Elaine Majerus, Borong Wang, Yang Wang, Patricia Nieters, Mary Clare Derfler, Angela Oliver, Cassandra Hardy, Riyaz Bashir, Ronald Winokur, Natalie Weger, Minhaj S. Khaja, Aditya Sharma, Naganathan Mani, Pavan Kavali, Siddhant Thukral, Leslie L. Lake, Kathryn Mikkelsen, Sameer Parpia, the C-TRACT Trial Investigators* 2026-06-18 Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. https://www.nejm.org/doi/full/10.1056/NEJMoa2602167?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602167 Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski, the TOWAR Study Group* 2026-06-18 Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... https://www.nejm.org/doi/full/10.1056/NEJMe2603048?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603048 Ronald Luiz Gomes Flumignan, Luís Carlos Uta Nakano 2026-06-18 Stenting for Post-Thrombotic Syndrome — A Step Forward Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and... https://www.nejm.org/doi/full/10.1056/NEJMe2605735?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605735 Susan E. Rowell, Selwyn O. Rogers Jr. 2026-06-18 Prehospital Whole Blood for Traumatic Hemorrhage — Consistent Evidence from Two Randomized Trials